立体定向放射外科治疗泌乳素瘤的获益与风险:国际多中心队列研究
治疗前PRL≤270 ng/ml是内分泌缓解的预测因素,边缘剂量增加与更好的内分泌控制相关。
要点
- SRS治疗后3、5、8年内分泌缓解率分别为28%、41%、54%。
- 治疗前PRL≤270 ng/ml预测内分泌缓解,边缘剂量增加改善内分泌控制。
核心结论
- 对于药物难治性或残留/复发性泌乳素瘤,SRS在内分泌缓解、内分泌控制和肿瘤控制方面疗效显著。
- 新发垂体功能减退是最常见的不良事件。
主要发现
- SRS后3、5、8年内分泌缓解率分别为28%、41%、54%。
- 25%患者(72/289)出现新发激素缺乏。
- 3%患者(9/269)出现新发视觉并发症,5%患者(13/285)记录到肿瘤进展。
- 治疗前PRL≤270 ng/ml是内分泌缓解的预测因素(p=0.005,校正HR 0.487)。
关键数值与推荐
- 内分泌缓解定义为PRL水平正常且无需多巴胺激动剂治疗。
- 内分泌控制定义为内分泌缓解或使用多巴胺激动剂治疗下PRL≤30 ng/ml。
临床怎么用
- 对于药物难治性或残留/复发性泌乳素瘤,SRS可作为治疗选择,需权衡内分泌缓解获益与新发垂体功能减退风险。
- 治疗前PRL水平和边缘剂量可能有助于预测内分泌缓解和控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The most common functioning pituitary adenoma is prolactinoma. Patients with medically refractory or residual/recurrent tumors that are not amenable to resection can be treated with stereotactic radiosurgery (SRS). The aim of this multicenter study was to evaluate the role of SRS for treating prolactinomas. METHODS: This retrospective study included prolactinomas treated with SRS between 1997 and 2016 at ten institutions. Patients' clinical and treatment parameters were investigated. Patients were considered to be in endocrine remission when they had a normal level of prolactin (PRL) without requiring dopamine agonist medications. Endocrine control was defined as endocrine remission or a controlled PRL level ≤ 30 ng/ml with dopamine agonist therapy. Other outcomes were evaluated including new-onset hormone deficiency, tumor recurrence, and new neurological complications. RESULTS: The study cohort comprised 289 patients. The endocrine remission rates were 28%, 41%, and 54% at 3, 5, and 8 years after SRS, respectively. Following SRS, 25% of patients (72/289) had new hormone deficiency. Sixty-three percent of the patients (127/201) with available data attained endocrine control. Three percent of patients (9/269) had a new visual complication after SRS. Five percent of the patients (13/285) were recorded as having tumor progression. A pretreatment PRL level ≤ 270 ng/ml was a predictor of endocrine remission (p = 0.005, adjusted HR 0.487). An increasing margin dose resulted in better endocrine control after SRS (p = 0.033, adjusted OR 1.087). CONCLUSIONS: In patients with medically refractory prolactinomas or a residual/recurrent prolactinoma, SRS affords remarkable therapeutic effects in endocrine remission, endocrine control, and tumor control. New-onset hypopituitarism is the most common adverse event.
引用
- Hung YC, Lee CC, Yang HC, et al. The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study. J Neurosurg. 2019. PMID: 31374549. doi:10.3171/2019.4.JNS183443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。